Transaction · 0001464583-26-000008
KNSAKiniksa Pharmaceuticals International, plc
Megna Michael R
Megna Michael R, CAO, reported an open-market or private sale at Kiniksa Pharmaceuticals International, plc involving 4600.000000 shares for an estimated $369380.00. Reported holdings after the transaction were 29062.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Open-market sellSEC transaction code SCAO
- Trade date
- Sep 03, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 33,662 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
KNSA price since this filing
Daily closing prices, with the filing date and available return windowsKNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -5.6%1w ago -0.8%1d ago -0.7%
Returns since7d -5.0%30d -5.8%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001464583-26-000008 Class A Ordinary Share
- Transaction date
- Sep 03, 2026 Filed Sep 03, 2026, 08:40 PM · 0d delay
- Shares
- 4,600 sh $80.30 per share
- Estimated value
- -$369k Computed from shares × price
- Holdings after
- 29,062 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
CHIEF ACCOUNTING OFFICER
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. T…
- F2
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F3
This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
- F4
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
- F5
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…
- F6
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
- F7
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
- F8
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
- F9
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Related transactions
Same SEC filing0 other transactions
Recent company activity
KNSA0 recent txs